Friday 4th August 2023 |
Text too small? |
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb has announced his intention to retire as a director of the company, following the recruitment and appointment of a replacement independent director to the Board.
Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service during his 11-year tenure. His deep industry knowledge and experience has enabled him to make a significant contribution to the growth and success of AFT, and it has been a privilege to work alongside him.”
The Board will now commence a recruitment process for a replacement director, and further details will be announced in due course.
Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals (ASX:AFP, NZX: AFT )
www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.
No comments yet
PaySauce Quarterly Market Update - June 2024
Manawa Energy - Annual Meeting and Director Nominations
SKO - Annual Shareholders Meeting Materials
VGL - 2024 Half Year Results Announcement Date
TruScreen Group Limited ("TRU") - Late Annual Report
ARB - Sale of In Vitro Business
NZK - Change of External Auditor
SCT - Scott lands major contracts for MHL in Europe
July 2nd Morning Report
PFI - Details of FP24 Results Webcast